A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept
Table 1
Characteristics of all studies included in the meta-analysis.
CNV confirmed by OCT and FFA at baseline visit IRF/SRF present at least for 3 months prior to conversion and treated with 3 monthly anti-VEGF injections
IRF, SRF, or sub-RPE with adjacent IRF/SRF on OCT At least 12 months of anti-VEGF treatment prior to conversion VA > 20/400 at conversion At least 12 months of follow-up